Text Size:AAA

BLyS/TNFSF13B Protein, Antibody, ELISA Kit, cDNA Clone

Human BLyS/TNFSF13B Protein

Description: Active
Expression host: Human Cells
  • Slide 1
10056-H01H-10
10056-H01H-20
10 µg / $70
20 µg / $120
Add to Cart
Description: Active
Expression host: Human Cells
  • Slide 1
10056-HNCH-20
10056-HNCH-50
20 µg / $120
50 µg / $290
Add to Cart
Expression host: E. coli
  • Slide 1
10056-HNAE-20
10056-HNAE-50
20 µg / $150
50 µg / $290
Add to Cart

Cynomolgus BLyS/TNFSF13B Protein

Expression host: Human Cells
  • Slide 1
90267-C01H-20
90267-C01H-50
20 µg / $120
50 µg / $290
Add to Cart

BLyS/TNFSF13B Related Areas

BLyS/TNFSF13B Related Pathways

BLyS/TNFSF13B Related Product

BLyS/TNFSF13B Related Information

BLyS/TNFSF13B Background

Gene Summary: The protein encoded by TNFSF13B gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for receptors TNFRSF13B/TACI, TNFRSF17/BCMA, and TNFRSF13C/BAFFR. This cytokine is expressed in B cell lineage cells, and acts as a potent B cell activator. It has been also shown to play an important role in the proliferation and differentiation of B cells. Alternatively spliced transcript variants encoding distinct isoforms have been identified. [provided by RefSeq, Mar 2011]
General information above from NCBI
Subunit structure: Homotrimer. Isoform 2 heteromultimerizes with isoform 1, probably limiting the amount of functional isoform 1 on the cell surface. Isoform 3 is unlikely form trimers or bind to BAFF receptors.
Subcellular location: Cell membrane; Single-pass type II membrane protein.
Tumor necrosis factor ligand superfamily member 13b, soluble form: Secreted.
Tissue specificity: Abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. Also found in the spleen, lymph node, bone marrow, T- cells and dendritic cells. A lower expression seen in placenta, heart, lung, fetal liver, thymus, and pancreas. Isoform 2 is expressed in many myeloid cell lines.
Induction: Up-regulated by exposure to IFNG/IFN-gamma. Down- regulated by phorbol myristate acetate/ionomycin treatment.
Post-translational: The soluble form derives from the membrane form by proteolytic processing.
Isoform 2 is not efficiently shed from the membrane unlike isoform 1 (By similarity).
N-glycosylated.
Sequence similarities: Belongs to the tumor necrosis factor family.
General information above from UniProt

B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors is a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). BLyS as an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.

BLyS/TNFSF13B Altermative Names

BLyS/TNFSF13B Related Studies

  • Nardelli B, et al. (2002) B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases. Leuk Lymphoma. 43(7): 1367-73.
  • Stohl W. (2006) Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 6(4): 51-8.
  • Cancro MP, et al. (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 119(5): 1066-73.
  • Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"